At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...

Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

However, a report last year from The House of Representatives and another more recently from the Federal Trade Commission (FTC) argue that PBMs have used this position to drive up drug costs for ...

The report shows that PBMs made over $7.3 billion in extra profits from dispensing specialty generic drugs during the study ...

An earlier FTC report published in July 2024 argued that the six largest PBMs were effectively running a monopoly that gave them enormous power over the price of medicines and allowed them to ...

Sen. James Lankford has been trying to pass legislation in response to an industry he believes will leave small towns without ...

Carl Schmid, executive director of the HIV+Hepatitis Policy Institute in Washington, D.C., talks about the problems associated with generic HIV PrEP drug markups and potential ways to fix it.

Indeed, condemnation of PBMs is one of the rare points where ... had finally reached a boiling point. In July, the FTC published a damning report from a two-year investigation of the industry ...

Oil and gas production in the United States is hitting record highs, easily outpacing consumption growth and fueling an export boom that in 2020 achieved the country's first trade surplus in energy ...